Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Look, Ma! No pneumococcus!

C Potera

    Environmental Health Perspectives
    |May 26, 1999
    PubMed
    Summary
    This summary is machine-generated.

    A new pneumococcal vaccine shows 100% efficacy against the deadliest forms of pneumococcal disease, bacterial meningitis and bacteremia. This breakthrough offers significant protection for infants and young children against severe pneumococcus infections.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Mountain Nutrition: Common Sense May Prevent Cachexia.

    The Physician and sportsmedicine·2016
    Same author

    Women in Sports: The Price of Participation.

    The Physician and sportsmedicine·2016
    Same author

    Knee Injuries on the Slopes Remain a Binding Problem.

    The Physician and sportsmedicine·2016
    Same author

    Knee Braces: Questions Raised About Performance.

    The Physician and sportsmedicine·2016
    Same author

    Help patients get serious about sunscreens.

    The Physician and sportsmedicine·2010
    Same author

    Smelling in color: a rainbow of possibilities.

    Environmental health perspectives·2001
    Same journal

    Time-Varying Exposure to Element Mixtures and Children's Cognition at 5 Years of Age: Findings from the New Hampshire Birth Cohort Study.

    Environmental health perspectives·2026
    Same journal

    Effect of Household Air Pollution on the Gut Microbiome and Virome of Adult Women Living in Uganda.

    Environmental health perspectives·2026
    Same journal

    Comparison of Temperature-Mortality Associations across the Middle East Using Different Exposure Estimation Approaches.

    Environmental health perspectives·2026
    Same journal

    Workflow for Statistical Analysis of Environmental Mixtures.

    Environmental health perspectives·2026
    Same journal

    Effects of Extreme Heat Exposure on Heatstroke and Liver Injury in Mice: The Role of PPARα.

    Environmental health perspectives·2026
    Same journal

    Evaluating the Effects of Neburon Exposure on Ovarian Folliculogenesis Using Zebrafish and Mouse Granulosa Cell Line.

    Environmental health perspectives·2026
    See all related articles

    Area of Science:

    • Bacteriology
    • Vaccinology
    • Pediatric Infectious Diseases

    Background:

    • Pneumococcal diseases, caused by Streptococcus pneumoniae, lead to millions of doctor visits and over a million deaths globally each year.
    • Pneumonia and otitis media are common manifestations, with children under five accounting for a significant proportion of fatalities.
    • Bacterial meningitis and bacteremia represent the most lethal pneumococcal infections.

    Purpose of the Study:

    • To evaluate the efficacy of a novel pneumococcal vaccine in preventing severe pneumococcal diseases.
    • To assess the vaccine's impact on bacterial meningitis and bacteremia in infants.

    Main Methods:

    • A three-year, Phase III clinical trial was conducted involving 38,000 infants.
    • Participants were randomized to receive either the new pneumococcal vaccine or a placebo.

    Related Experiment Videos

  • Efficacy rates against specific pneumococcal afflictions were meticulously recorded.

    • Main Results:

    • The new pneumococcal vaccine demonstrated a 100% efficacy rate against bacterial meningitis.
    • The vaccine also achieved 100% efficacy against bacteremia, the two most deadly pneumococcal conditions.
    • The trial involved a large cohort, ensuring robust statistical power.

    Conclusions:

    • The novel pneumococcal vaccine is highly effective in preventing the most severe outcomes of Streptococcus pneumoniae infection.
    • This vaccine represents a significant advancement in pediatric infectious disease prevention.
    • Widespread vaccination could dramatically reduce pneumococcal disease mortality, especially in young children.